This recombinant monoclonal antibody is developed as a research-grade biosimilar to CDX014, targeting HAVCR1 (Hepatitis A Virus Cellular Receptor 1), also known as TIM-1 or KIM-1. HAVCR1 functions as a phosphatidylserine receptor involved in the clearance of apoptotic cells and regulation of immune responses. This type I membrane protein plays significant roles in T cell activation, tolerance, and autoimmunity. HAVCR1 is markedly upregulated in kidney injury and serves as a biomarker for acute kidney injury and renal cell carcinoma. Additionally, aberrant expression has been associated with various malignancies and immune-mediated diseases, making it an important target for therapeutic and diagnostic research.
CDX014 is a humanized anti-HAVCR1 monoclonal antibody originally developed for antibody-drug conjugate applications in oncology, particularly targeting renal cell carcinoma where HAVCR1 shows elevated expression on tumor cells. This biosimilar antibody provides researchers with a reliable tool for investigating HAVCR1 biology, exploring its role in cancer progression, kidney pathology, and immune regulation, as well as supporting preclinical studies in oncology and nephrology research.
Email: support@cusabio.com
Distributors Worldwide